At a population level, large genomic datasets combined with AI and polygenic modeling could support predictive testing for SCD-associated SCN5A variants, enabling preventive strategies before symptoms appear, though careful ethical and familial considerations remain essential (57). This evidence concerns the gene SCN5A and Schnyder corneal dystrophy.